Shares in CRISPR genome-editing biopharma company Caribou Biosciences (Nasdaq: CRBU) were worth 37% more at mid-morning Friday than they were at Wednesday’s close.
The reason was a potential scientific breakthrough that could have importance well beyond the Californian company’s share price.
On Thursday, Caribou announced initial results demonstrating a 100% overall response rate (ORR) and 80% complete response rate (CR) in cohort one from its ANTLER Phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze